These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 6372984)
1. Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease. Citrin DL; Elson P; DeWys WD Cancer; 1984 Jul; 54(1):13-7. PubMed ID: 6372984 [TBL] [Abstract][Full Text] [Related]
2. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer. Citrin DL; Hogan TF Cancer; 1982 Jul; 50(2):201-6. PubMed ID: 7200827 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer: evaluation of response to treatment, response criteria, and the need for standardization of the reporting of results. Aabo K Eur J Cancer Clin Oncol; 1987 Feb; 23(2):231-6. PubMed ID: 3327696 [TBL] [Abstract][Full Text] [Related]
4. A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. DeWys WD; Begg CB; Brodovsky H; Creech R; Khandekar J Prostate; 1983; 4(1):1-11. PubMed ID: 6340081 [TBL] [Abstract][Full Text] [Related]
5. Comparison of adriamycin (NSC-123127) and 5-fluorouracil (NSC-19893) in advanced prostatic cancer. DeWys WD Cancer Chemother Rep; 1975; 59(1):215-7. PubMed ID: 1093668 [No Abstract] [Full Text] [Related]
6. [The evaluation of chemotherapy of relapse in prostatic cancer with new response criteria]. Isaka S; Fuse H; Akaza H; Moriyama N; Usami M; Kotake T; Matsumura Y; Imai K; Yamanaka H; Matsumoto K Hinyokika Kiyo; 1987 Sep; 33(9):1389-95. PubMed ID: 3434494 [TBL] [Abstract][Full Text] [Related]
7. Comparison of adriamycin (NSC-123127) and the combination of 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in advanced prostatic cancer: a preliminary report. Eagan RT; Utz DC; Myers RP; Furlow WL Cancer Chemother Rep; 1975; 59(1):203-7. PubMed ID: 1093666 [TBL] [Abstract][Full Text] [Related]
8. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. Logothetis CJ; Samuels ML; von Eschenbach AC; Trindade A; Ogden S; Grant C; Johnson DE J Clin Oncol; 1983 Jun; 1(6):368-79. PubMed ID: 6422006 [TBL] [Abstract][Full Text] [Related]
9. Routine interval computed tomography to detect new soft-tissue disease might be unnecessary in patients with androgen-independent prostate cancer and metastasis only to bone. Wu SL; Jones E; Gulley JL; Arlen PM; Chen CC; Figg WD; Dahut WL BJU Int; 2007 Mar; 99(3):525-8. PubMed ID: 17155971 [TBL] [Abstract][Full Text] [Related]
11. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Lin CC; Hsu CH; Chen J; Tsai TC; Cheng AL; Pu YS Anticancer Res; 2001; 21(2B):1385-90. PubMed ID: 11396219 [TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. Wozniak AJ; Blumenstein BA; Crawford ED; Boileau M; Rivkin SE; Fletcher WS Cancer; 1993 Jun; 71(12):3975-8. PubMed ID: 8508363 [TBL] [Abstract][Full Text] [Related]
13. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Eagan RT; Hahn RG; Myers RP Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515 [No Abstract] [Full Text] [Related]
14. A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer. Citrin DL; Kies MS; Wallemark CB; Khandekar J; Kaplan E; Camacho F; Lind R Cancer; 1985 Aug; 56(3):457-60. PubMed ID: 4005808 [TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. Nicholson BP; Paul DM; Hande KR; Shyr Y; Meshad M; Cohen A; Johnson DH Clin Breast Cancer; 2000 Jul; 1(2):136-43; discussion 144. PubMed ID: 11899652 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. Smith DC; Esper P; Strawderman M; Redman B; Pienta KJ J Clin Oncol; 1999 Jun; 17(6):1664-71. PubMed ID: 10561202 [TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. Verweij J; Lee SM; Ruka W; Buesa J; Coleman R; van Hoessel R; Seynaeve C; di Paola ED; van Glabbeke M; Tonelli D; Judson IR J Clin Oncol; 2000 May; 18(10):2081-6. PubMed ID: 10811673 [TBL] [Abstract][Full Text] [Related]
18. Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. Sogani PC; Vagaiwala MR; Whitmore WF Cancer; 1984 Aug; 54(4):744-50. PubMed ID: 6378356 [TBL] [Abstract][Full Text] [Related]
20. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]